Drug Target Hunters
Built with Claude: Life SciencesOur analysis combines monogenic immune-disease genes, evolutionary constraint, GWAS, and genome-scale CRISPRi perturb-seq in primary human CD4+ T cells, ranking all 18,692 genes with a positive-unlabeled model that uses no drug-approval information as input. Two findings: (1) it recovers known immune-drug targets at 8.3-fold enrichment in its top 100 under group-aware cross-validation; (2) in a blind test of novelty, 24% (6/25) of its top novel nominations are already in clinical development, versus 2% (1/50) of matched controls (Fisher exact odds ratio 15.5, p=0.005). It independently recovers the active pipeline and nominates the next candidates (MAP3K14/NIK, RORC/RORgt, MALT1) on the antigen-receptor to NF-kB axis.
Team
Placement
Participant
